173 related articles for article (PubMed ID: 25567759)
1. CD22ΔE12 as a molecular target for corrective repair using RNA trans-splicing: anti-leukemic activity of a rationally designed RNA trans-splicing molecule.
Uckun FM; Qazi S; Ma H; Reaman GH; Mitchell LG
Integr Biol (Camb); 2015 Feb; 7(2):237-49. PubMed ID: 25567759
[TBL] [Abstract][Full Text] [Related]
2. Development of Polypeptide-based Nanoparticles for Non-viral Delivery of CD22 RNA Trans-splicing Molecule as a New Precision Medicine Candidate Against B-lineage ALL.
Uckun FM; Mitchell LG; Qazi S; Liu Y; Zheng N; Myers DE; Song Z; Ma H; Cheng J
EBioMedicine; 2015 Jul; 2(7):649-59. PubMed ID: 26288837
[TBL] [Abstract][Full Text] [Related]
3. CD22ΔE12 as a molecular target for RNAi therapy.
Uckun FM; Ma H; Cheng J; Myers DE; Qazi S
Br J Haematol; 2015 May; 169(3):401-14. PubMed ID: 25659406
[TBL] [Abstract][Full Text] [Related]
4. CD22 EXON 12 deletion as a pathogenic mechanism of human B-precursor leukemia.
Uckun FM; Goodman P; Ma H; Dibirdik I; Qazi S
Proc Natl Acad Sci U S A; 2010 Sep; 107(39):16852-7. PubMed ID: 20841423
[TBL] [Abstract][Full Text] [Related]
5. A rationally designed nanoparticle for RNA interference therapy in B-lineage lymphoid malignancies.
Uckun FM; Qazi S; Ma H; Yin L; Cheng J
EBioMedicine; 2014 Dec; 1(2-3):141-155. PubMed ID: 25599086
[TBL] [Abstract][Full Text] [Related]
6. CD22 Exon 12 deletion is a characteristic genetic defect of therapy-refractory clones in paediatric acute lymphoblastic leukaemia.
Ma H; Qazi S; Ozer Z; Gaynon P; Reaman GH; Uckun FM
Br J Haematol; 2012 Jan; 156(1):89-98. PubMed ID: 22017452
[TBL] [Abstract][Full Text] [Related]
7. Identification and targeting of CD22ΔE12 as a molecular RNAi target to overcome drug resistance in high-risk B-lineage leukemias and lymphomas.
Uckun FM; Qazi S
Cancer Drug Resist; 2018; 1():30-47. PubMed ID: 31788667
[TBL] [Abstract][Full Text] [Related]
8. Spleen tyrosine kinase (Syk) deficiency in childhood pro-B cell acute lymphoblastic leukemia.
Goodman PA; Wood CM; Vassilev A; Mao C; Uckun FM
Oncogene; 2001 Jul; 20(30):3969-78. PubMed ID: 11494125
[TBL] [Abstract][Full Text] [Related]
9. Constitutive function of the Ikaros transcription factor in primary leukemia cells from pediatric newly diagnosed high-risk and relapsed B-precursor ALL patients.
Uckun FM; Ma H; Ishkhanian R; Arellano M; Shahidzadeh A; Termuhlen A; Gaynon PS; Qazi S
PLoS One; 2013; 8(11):e80732. PubMed ID: 24278314
[TBL] [Abstract][Full Text] [Related]
10. Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial.
Wayne AS; Kreitman RJ; Findley HW; Lew G; Delbrook C; Steinberg SM; Stetler-Stevenson M; Fitzgerald DJ; Pastan I
Clin Cancer Res; 2010 Mar; 16(6):1894-903. PubMed ID: 20215554
[TBL] [Abstract][Full Text] [Related]
11. Liposomal Nanoparticles of a Spleen Tyrosine Kinase P-Site Inhibitor Amplify the Potency of Low Dose Total Body Irradiation Against Aggressive B-Precursor Leukemia and Yield Superior Survival Outcomes in Mice.
Uckun FM; Myers DE; Cheng J; Qazi S
EBioMedicine; 2015 Jun; 2(6):554-62. PubMed ID: 26285772
[TBL] [Abstract][Full Text] [Related]
12. Screening of Variations in CD22 Gene in Children with B-Precursor Acute Lymphoblastic Leukemia.
Aslar Oner D; Akin DF; Sipahi K; Mumcuoglu M; Ezer U; Kürekci AE; Akar N
Genet Test Mol Biomarkers; 2016 Sep; 20(9):552-5. PubMed ID: 27486888
[TBL] [Abstract][Full Text] [Related]
13. K14 mRNA reprogramming for dominant epidermolysis bullosa simplex.
Wally V; Brunner M; Lettner T; Wagner M; Koller U; Trost A; Murauer EM; Hainzl S; Hintner H; Bauer JW
Hum Mol Genet; 2010 Dec; 19(23):4715-25. PubMed ID: 20861136
[TBL] [Abstract][Full Text] [Related]
14. Expression of aberrantly spliced oncogenic ikaros isoforms in childhood acute lymphoblastic leukemia.
Sun L; Goodman PA; Wood CM; Crotty ML; Sensel M; Sather H; Navara C; Nachman J; Steinherz PG; Gaynon PS; Seibel N; Vassilev A; Juran BD; Reaman GH; Uckun FM
J Clin Oncol; 1999 Dec; 17(12):3753-66. PubMed ID: 10577847
[TBL] [Abstract][Full Text] [Related]
15. Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia.
Haso W; Lee DW; Shah NN; Stetler-Stevenson M; Yuan CM; Pastan IH; Dimitrov DS; Morgan RA; FitzGerald DJ; Barrett DM; Wayne AS; Mackall CL; Orentas RJ
Blood; 2013 Feb; 121(7):1165-74. PubMed ID: 23243285
[TBL] [Abstract][Full Text] [Related]
16. Characterization of the anti-CD22 targeted therapy, moxetumomab pasudotox, for B-cell precursor acute lymphoblastic leukemia.
Kinjyo I; Matlawska-Wasowska K; Chen X; Monks NR; Burke P; Winter SS; Wilson BS
Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28449314
[TBL] [Abstract][Full Text] [Related]
17. The design and optimization of RNA trans-splicing molecules for skin cancer therapy.
Gruber C; Koller U; Murauer EM; Hainzl S; Hüttner C; Kocher T; South AP; Hintner H; Bauer JW
Mol Oncol; 2013 Dec; 7(6):1056-68. PubMed ID: 23998959
[TBL] [Abstract][Full Text] [Related]
18. CD22 Exon 12 Deletion as an Independent Predictor of Poor Treatment Outcomes in B-ALL.
Qazi S; Uckun FM
Cancers (Basel); 2023 Mar; 15(5):. PubMed ID: 36900389
[TBL] [Abstract][Full Text] [Related]
19. Promiscuity of pre-mRNA spliceosome-mediated trans splicing: a problem for gene therapy?
Kikumori T; Cote GJ; Gagel RF
Hum Gene Ther; 2001 Jul; 12(11):1429-41. PubMed ID: 11485634
[TBL] [Abstract][Full Text] [Related]
20. A reporter-based screen to identify potent 3' trans-splicing molecules for endogenous RNA repair.
Murauer EM; Koller U; Hainzl S; Wally V; Bauer JW
Hum Gene Ther Methods; 2013 Feb; 24(1):19-27. PubMed ID: 23320616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
